At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6,901 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PMS Study of MicardisPlus Tablet
In Brief
An observational study for Hypertension. Completed, enrolled 6,901 participants across 326 sites.
Detailed Summary
This Post Marketing Surveillance (PMS) study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market: 1. Unexpected adverse drug reactions (especially, serious adverse events (SAEs)) 2. Frequency of incidence and its change in adverse events (AEs) 3. Factors on the safety profile of the study drug 4. Factors on the efficacy profile of the study drug
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2003
First PostedApr 2008
Primary CompletionJul 2008
TodayJul 2026
First PostedApr 16, 2008
Enrollment StartSep 1, 2003
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.2 years ago